Open AccessIndirect Comparisons via Sorafenib for the Comparative Effectiveness of Two PD-1/PD-L1 Inhibitors to Treat Advanced Hepatocellular Carcinoma Patients without Prior Systemic Therapies
Author(s) -
Yawen Jiang,
Cai Dan,
Si Shi
Publication year - 2022
Publication title -
clinical epidemiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.868
H-Index - 58
ISSN - 1179-1349
DOI - 10.2147/clep.s352045
Subject(s) - medicine , sorafenib , hepatocellular carcinoma , hazard ratio , oncology , atezolizumab , regimen , bevacizumab , proportional hazards model , progression free survival , pembrolizumab , confidence interval , overall survival , cancer , immunotherapy , chemotherapy
Advanced hepatocellular carcinoma (HCC) represents a major public health threat. Several emerging combination therapies have shown promising results for the first-line treatment of advanced HCC. The present study compared the efficacy of atezolizumab plus bevacizumab (AB) with lenvatinib plus pembrolizumab (LP), which were two of the leading combination therapies.